Approval for vaccines accelerates India's journey to be Covid-free: Modi

Modi said it will make every Indian proud that both the vaccines are made in India

Narendra Modi | Image: Twitter
He once again extended his gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all ''Corona warriors''.
Press Trust of India New Delhi
2 min read Last Updated : Jan 03 2021 | 12:12 PM IST

Hailing the approval given to two coronavirus vaccines as a "decisive turning point" in the spirited fight against the pandemic, Prime Minister Narendra Modi said on Sunday that this will accelerate the process for India to become a COVID-free nation.

In a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.

"This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion," he said, congratulting the nation, scientists and innovators.

He once again extended his gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all 'Corona warriors' for the outstanding work they have done in adverse circumstances, and said the nation will remain eternally grateful to them for saving many lives.

"A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators," he tweeted.

The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with Oxford-AstraZeneca to manufacture Covishield.

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The approval by the DCGI was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Narendra ModiCoronavirus VaccineSerum Institute of IndiaBharat Biotech

First Published: Jan 03 2021 | 12:04 PM IST

Next Story